Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with
 ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.
Inclusion Criteria:

 -  Age > 18 with chronic genotype 2 or 3 HCV infection

 -  HCV RNA > 10,000 IU/mL at screening

 -  Subjects must be treatment naive or treatment experienced

 -  Presence or absence of cirrhosis; a liver biopsy may be required

 -  Healthy according to medical history and physical examination with the exception of
 HCV diagnosis

 -  Agree to use two forms of highly effective contraception for the duration of the study
 and 6 months after the last dose of study medication

 Exclusion Criteria:

 -  Prior use of any other inhibitor of the HCV NS5B Polymerase

 -  History of any other clinically significant chronic liver disease

 -  Evidence of or history of decompensated liver disease

 -  HIV or chronic hepatitis B virus (HBV) infection

 -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved
 skin cancers)

 -  Chronic use of immunosuppressive agents or immunomodulatory agents

 -  History or current evidence of any condition, therapy, laboratory abnormality or other
 circumstance that might confound the results of the study, or interfere with the
 subject's participation for the full duration of the study or not be in the best
 interest of the subject in the opinion of the investigator